Literature DB >> 9759585

Immunotherapy and experimental approaches for metastatic melanoma.

M B Atkins1.   

Abstract

This article reviews the clinical investigations involving recombinant cytokines (either alone or in combination with adoptive immunotherapy, toxicity reduction agents, or cytotoxic chemotherapy), vaccines, monoclonal antibodies or antibody conjugates, and gene therapy. These various approaches are reviewed for their current and potential roles in curing metastatic melanoma.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9759585     DOI： 10.1016/s0889-8588(05)70029-0

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  8 in total

1.  IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC.

Authors:  Gordana Konjević; Viktor Jović; Vladimir Jurisić; Sinisa Radulović; Svetislav Jelić; Ivan Spuzić
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

2.  Differential Antitumor Effects of IgG and IgM Monoclonal Antibodies and Their Synthetic Complementarity-Determining Regions Directed to New Targets of B16F10-Nex2 Melanoma Cells.

Authors:  Andrey S Dobroff; Elaine G Rodrigues; Maria A Juliano; Dayson M Friaça; Ernesto S Nakayasu; Igor C Almeida; Renato A Mortara; Jacqueline F Jacysyn; Gustavo P Amarante-Mendes; Walter Magliani; Stefania Conti; Luciano Polonelli; Luiz R Travassos
Journal:  Transl Oncol       Date:  2010-08-01       Impact factor: 4.243

3.  Enhanced anti-tumor activity of interferon-alpha in SOCS1-deficient mice is mediated by CD4⁺ and CD8⁺ T cells.

Authors:  Kristan D Guenterberg; Gregory B Lesinski; Bethany L Mundy-Bosse; Volodymyr I Karpa; Alena Cristina Jaime-Ramirez; Lai Wei; William E Carson
Journal:  Cancer Immunol Immunother       Date:  2011-05-21       Impact factor: 6.968

4.  Use of a nanoporous biodegradable miniature device to regulate cytokine release for cancer treatment.

Authors:  Hongyan He; Valerie Grignol; Volodymyr Karpa; Chi Yen; Krista LaPerle; Xiaoli Zhang; Natalie B Jones; Margaret I Liang; Gregory B Lesinski; W S Winston Ho; William E Carson; L James Lee
Journal:  J Control Release       Date:  2011-02-26       Impact factor: 9.776

Review 5.  Immunomodulatory cytokines as therapeutic agents for melanoma.

Authors:  Courtney Nicholas; Gregory B Lesinski
Journal:  Immunotherapy       Date:  2011-05       Impact factor: 4.196

Review 6.  Immunotherapy for melanoma: current status and perspectives.

Authors:  Doru T Alexandrescu; Thomas E Ichim; Neil H Riordan; Francesco M Marincola; Anna Di Nardo; Filamer D Kabigting; Constantin A Dasanu
Journal:  J Immunother       Date:  2010 Jul-Aug       Impact factor: 4.456

7.  Metastatic melanoma of the gallbladder: an unusual clinical presentation of acute cholecystitis.

Authors:  Spiridon Vernadakis; Georgios Rallis; Nikolaos Danias; Costas Serafimidis; Evangelos Christodoulou; Michail Troullinakis; Nikolaos Legakis; Georgios Peros
Journal:  World J Gastroenterol       Date:  2009-07-21       Impact factor: 5.742

8.  Periodically Pulsed Immunotherapy in a Mathematical Model of Tumor, CD4+ T Cells, and Antitumor Cytokine Interactions.

Authors:  Hsiu-Chuan Wei; Jui-Ling Yu; Chia-Yu Hsu
Journal:  Comput Math Methods Med       Date:  2017-11-09       Impact factor: 2.238
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.